{"protocolSection": {"identificationModule": {"nctId": "NCT02435277", "orgStudyIdInfo": {"id": "NS-0100-01E"}, "organization": {"fullName": "NuSirt Biopharma", "class": "INDUSTRY"}, "briefTitle": "An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients", "officialTitle": "An Extension of Protocol NS-0100-01 to Evaluate the Safety and Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Mono-therapy on Glycemic Control in Subjects With Type 2 Diabetes"}, "statusModule": {"statusVerifiedDate": "2017-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-10"}, "primaryCompletionDateStruct": {"date": "2015-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-04-13", "studyFirstSubmitQcDate": "2015-04-30", "studyFirstPostDateStruct": {"date": "2015-05-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-09-27", "resultsFirstSubmitQcDate": "2017-12-15", "resultsFirstPostDateStruct": {"date": "2017-12-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-12-18", "lastUpdatePostDateStruct": {"date": "2018-01-17", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "NuSirt Biopharma", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Study NS-0100-01E is an extension of Study NS-01-0100 designed to assess safety and longer term effect (i.e., additional 8 weeks) of various fixed-dose leucine and metformin combinations (NS-0100) versus standard metformin monotherapy on glycemic control in subjects with type 2 diabetes using HbA1c as the primary endpoint.", "detailedDescription": "This is a randomized, 8-week, extension of Study NS-0100-01, to evaluate the effect of various fixed-dose (FDC) combinations of leucine and metformin compared to standard metformin monotherapy on glycemic control.\n\nSubjects meeting all inclusion criteria and no exclusion criteria for the extension study, including completion of the 4-week treatment period of Study NS-0100-01 \\[Day 28/Visit 7\\]), will be eligible to enroll into the extension. During participation in the extension, subjects will continue to receive their assigned treatment based upon the randomization that occurred on Day 1 (Visit 4) of Study NS-0100-0. The study will include a total of 3 visits: Visit 1E (Day 28/Visit 7 of Study NS-0100-01), Visit 2E (Day 56/Week 8), and Visit 3E (Day 84/Week 12). Key assessments at Visit 2E and Visit 3E include HbA1c, fasting plasma glucose, and plasma insulin. In addition, 3-hour standardized meal tests will be performed on Day 28 (as part of the Study Termination \\[Visit 7\\] procedures of Study NS-0100-01 prior to enrolling into the extension) and at Study Termination for the extension (Visit 3E \\[Day 84/Week 12\\])."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["Diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 50, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Low Metformin", "type": "EXPERIMENTAL", "description": "3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin", "interventionNames": ["Drug: Low Metformin"]}, {"label": "Mid Metformin", "type": "EXPERIMENTAL", "description": "3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin", "interventionNames": ["Drug: Mid Metformin"]}, {"label": "High Metformin", "type": "EXPERIMENTAL", "description": "3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin", "interventionNames": ["Drug: High Metformin"]}, {"label": "Metformin Monotherapy", "type": "ACTIVE_COMPARATOR", "description": "3 Capsules BID each containing 283.3 mg of metformin BID (1,700 mg/Day) at Day 14.", "interventionNames": ["Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Low Metformin", "description": "1100 mg L Leucine in combination with 125 mg of Metformin BID", "armGroupLabels": ["Low Metformin"], "otherNames": ["Metformin, L-Leucince, Leucine"]}, {"type": "DRUG", "name": "Mid Metformin", "description": "1100 mg L Leucine in combination with 250mg Metformin BID", "armGroupLabels": ["Mid Metformin"], "otherNames": ["Metformin, Leucine, L-Leucine"]}, {"type": "DRUG", "name": "High Metformin", "description": "1100 mg of L Leucine in combination with 500 mg Metformin BID", "armGroupLabels": ["High Metformin"], "otherNames": ["Metformin, Leucine, L-Leucine"]}, {"type": "DRUG", "name": "Metformin", "description": "500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID", "armGroupLabels": ["Metformin Monotherapy"], "otherNames": ["Metformin, Leucine, L-Leucine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations", "description": "Change in HbA1c from Baseline (Day 1/Visit 1) of Study NS-0100-01 to Week 12 (Day 84/Visit 3E) in subjects receiving various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy.", "timeFrame": "Baseline and 12 weeks"}], "secondaryOutcomes": [{"measure": "Change in Fasting Plasma Glucose", "description": "Change in fasting plasma glucose from Baseline (Day 1/Visit 1) of Study NS-0100-01 to Week 12 (Day 84/Visit 3E). Based on the pre-specified mixed model inferential statistical analysis, there was an apparent dose-dependent relationship for the mean decrease from baseline in fasting plasma glucose for the fixed dose leucine amd metformin combination treatments A, B and C.", "timeFrame": "Baseline and 12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Has completed Study NS-0100-01, including all procedures required at Study Termination (Day 28/Visit 7) without major protocol deviations\n2. Is male, or female and, if female, meets all of the following criteria:\n\n   * Not breastfeeding\n   * Post-menopausal or negative pregnancy test result (human chorionic gonadotropin, beta subunit \\[\u03b2-hCG\\]) at Screening (Visit 1) (not required for hysterectomized females)\n   * If of childbearing potential (including perimenopausal women who have had a menstrual period within one year) and sexually active, must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as double barrier methods \\[male condom with spermicide, with or without cervical cap or diaphragm\\], implants, injectables, oral contraceptives \\[must have been using for at least the last 3 months\\], some intrauterine contraceptive devices, tubal ligation, or a vasectomized partner) during the entire duration of the study.\n3. Is able to read, understand, and sign the informed consent forms (ICF) and if applicable, an authorization to use and disclose protected health information form (consistent with health insurance portability and accountability act of 1996 \\[HIPAA\\] legislation), communicate with the investigator, and understand and comply with protocol requirements.\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria will be excluded from the study.\n\n1. Is undesirable as a study participant as judged by the investigator (e.g., exhibited poor compliance during Study NS-0100-01)\n2. Is expected to require treatment, or if currently on a stable dose, changes to their regimen of the following medications:\n\n   * Lipid-lowering agents\n   * Anti-hypertensive medications\n   * Thyroid replacement therapy\n   * Non-steroidal anti-inflammatory agents\n3. Is expected to require or undergo treatment with any of the following medications:\n\n   * Antidiabetes medications (with the exception of study medication \\[i.e., metformin\\])\n   * Oral or parenteral steroids.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Orville Kolterman, MD", "affiliation": "Pharmapace", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Catalina Research Institute", "city": "Chino", "state": "California", "zip": "91710", "country": "United States", "geoPoint": {"lat": 34.01223, "lon": -117.68894}}, {"facility": "Palm Beach Research", "city": "Palm Beach", "state": "Florida", "zip": "33409", "country": "United States", "geoPoint": {"lat": 26.70562, "lon": -80.03643}}, {"facility": "Meridien Research", "city": "Tampa", "state": "Florida", "zip": "33606", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "River Birch Research Alliance", "city": "Blue Ridge", "state": "Georgia", "zip": "3051313", "country": "United States", "geoPoint": {"lat": 34.86397, "lon": -84.32409}}, {"facility": "Meridian Research", "city": "Savannah", "state": "Georgia", "zip": "31406", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Streling Research Group", "city": "Cincinnati", "state": "Ohio", "zip": "45219", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Medical Research South", "city": "Charleston", "state": "South Carolina", "zip": "29407", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Meharry Medical College", "city": "Nashville", "state": "Tennessee", "zip": "37208", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Vanderbilt University Medical Center, Diabetes, Endocrinology, and Metabolism", "city": "Nashville", "state": "Tennessee", "zip": "37232", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Subjects meeting all inclusion criteria and no exclusion criteria for the NS-001-01-E, including completion of the 4-week treatment period of Study NS-0100-01 (Day 28/Visit 7), were eligible to enroll into the NS-001-01-E.", "recruitmentDetails": "Study NS-0100-01E was a randomized, double-blind 8-week extension of Study NS-0100-01 to evaluate the effect of various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy on glycemic control.", "groups": [{"id": "FG000", "title": "FDC 125", "description": "Leucine 1100mg +Metformin 125mg"}, {"id": "FG001", "title": "FDC 250", "description": "Leucine 1100mg +Metformin 250mg"}, {"id": "FG002", "title": "FDC 500", "description": "Leucine 1100mg +Metformin 500mg"}, {"id": "FG003", "title": "Control", "description": "850mg Metformin"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "16"}, {"groupId": "FG002", "numSubjects": "11"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "11"}, {"groupId": "FG003", "numSubjects": "11"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Study NS-0100-01E was the extension of Study NS-01-0100 designed to assess safety and longer term effect (ie, additional 8 weeks) of various fixed-dose leucine and metformin combinations (NS-0100) versus standard metformin monotherapy on glycemic control in subjects with type 2 diabetes.", "groups": [{"id": "BG000", "title": "FDC 125", "description": "Leucine 1100mg +Metformin 125mg"}, {"id": "BG001", "title": "FDC 250", "description": "Leucine 1100mg +Metformin 250mg"}, {"id": "BG002", "title": "FDC 500", "description": "Leucine 1100mg +Metformin 500mg"}, {"id": "BG003", "title": "Control", "description": "850mg Metformin"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "11"}, {"groupId": "BG004", "value": "50"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "40"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "10"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "51.8", "spread": "10.81"}, {"groupId": "BG001", "value": "56.1", "spread": "8.24"}, {"groupId": "BG002", "value": "59.8", "spread": "9.01"}, {"groupId": "BG003", "value": "60.5", "spread": "8.77"}, {"groupId": "BG004", "value": "56.9", "spread": "9.52"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "29"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "21"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "19"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "31"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "13"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "36"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "93.343", "spread": "19.0179"}, {"groupId": "BG001", "value": "91.314", "spread": "18.7664"}, {"groupId": "BG002", "value": "87.497", "spread": "21.2259"}, {"groupId": "BG003", "value": "90.500", "spread": "18.4163"}, {"groupId": "BG004", "value": "90.782", "spread": "18.8230"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "(kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.298", "spread": "4.4952"}, {"groupId": "BG001", "value": "31.647", "spread": "6.3242"}, {"groupId": "BG002", "value": "28.627", "spread": "4.5195"}, {"groupId": "BG003", "value": "32.677", "spread": "5.3808"}, {"groupId": "BG004", "value": "31.606", "spread": "5.4597"}]}]}]}, {"title": "Fasting Plasma Glucose", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "173.5", "spread": "31.13"}, {"groupId": "BG001", "value": "150.5", "spread": "26.78"}, {"groupId": "BG002", "value": "179.2", "spread": "36.04"}, {"groupId": "BG003", "value": "177.1", "spread": "53.67"}, {"groupId": "BG004", "value": "168.2", "spread": "38.00"}]}]}]}, {"title": "Haemoglobin A1c (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.56", "spread": "0.644"}, {"groupId": "BG001", "value": "7.83", "spread": "0.769"}, {"groupId": "BG002", "value": "7.84", "spread": "0.545"}, {"groupId": "BG003", "value": "7.92", "spread": "0.645"}, {"groupId": "BG004", "value": "7.79", "spread": "0.661"}]}]}]}, {"title": "Previous Metformin experience", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "No Previous Experience", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "8"}]}]}, {"title": "Prior taken metformin: No Abdominal side effects", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "35"}]}]}, {"title": "Prior taken metformin: Had abdominal side effects", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations", "description": "Change in HbA1c from Baseline (Day 1/Visit 1) of Study NS-0100-01 to Week 12 (Day 84/Visit 3E) in subjects receiving various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy.", "populationDescription": "Mixed Model Inferential Statistical Analysis of HbA1c change from day 1-day 84 Evaluable Population (n=43)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent HbA1c", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "FDC 125", "description": "Leucine 1100mg +Metformin 125mg"}, {"id": "OG001", "title": "FDC 250", "description": "Leucine 1100mg +Metformin 250mg"}, {"id": "OG002", "title": "FDC 500", "description": "Leucine 1100mg +Metformin 500mg"}, {"id": "OG003", "title": "Control", "description": "850mg Metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.10", "spread": "0.756"}, {"groupId": "OG001", "value": "-0.12", "spread": "0.987"}, {"groupId": "OG002", "value": "-0.05", "spread": "0.807"}, {"groupId": "OG003", "value": "-0.83", "spread": "0.627"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "Mixed Model Inferential Statistical Analysis of HbA1c change from day 1-day 84 Evaluable Population (n=43)", "nonInferiorityType": "OTHER", "pValue": "0.0475", "pValueComment": "Total daily dose is twice the respective dose, Pairwise Comparison using Control as the Reference Group", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "OTHER", "pValue": "0.0912", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "OTHER", "pValue": "0.0458", "statisticalMethod": "ANCOVA"}]}, {"type": "SECONDARY", "title": "Change in Fasting Plasma Glucose", "description": "Change in fasting plasma glucose from Baseline (Day 1/Visit 1) of Study NS-0100-01 to Week 12 (Day 84/Visit 3E). Based on the pre-specified mixed model inferential statistical analysis, there was an apparent dose-dependent relationship for the mean decrease from baseline in fasting plasma glucose for the fixed dose leucine amd metformin combination treatments A, B and C.", "populationDescription": "Mixed Model Inferential Statistical Analysis of Fasting Plasma Glucose change from day 1-day 84 in Evaluable Population (n=43)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and 12 weeks", "groups": [{"id": "OG000", "title": "FDC 125", "description": "Leucine 1100mg +Metformin 125mg"}, {"id": "OG001", "title": "FDC 250", "description": "Leucine 1100mg +Metformin 250mg"}, {"id": "OG002", "title": "FDC 500", "description": "Leucine 1100mg +Metformin 500mg"}, {"id": "OG003", "title": "Control", "description": "850mg Metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "11"}, {"groupId": "OG003", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.8", "spread": "22.29"}, {"groupId": "OG001", "value": "11.2", "spread": "22.37"}, {"groupId": "OG002", "value": "-4.3", "spread": "39.91"}, {"groupId": "OG003", "value": "-36.3", "spread": "45.47"}]}]}], "analyses": [{"groupIds": ["OG000", "OG003"], "groupDescription": "Mixed Model Inferential Statistical Analysis of Fssting Plasma Glucose change from day 1-day 84 in Evaluable Population (n=43)", "nonInferiorityType": "OTHER", "pValue": "0.26", "pValueComment": "Total daily dose is twice the respective dose Pairwise Comparison using Treatment D as the Reference Group", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "OTHER", "pValue": "0.0083", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "OTHER", "pValue": "0.0317", "statisticalMethod": "ANCOVA"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "84 days", "description": "Treatment-Energent Adverse Event (TEAE) is defined as an adverse event occurring on or after the first dose of randomized study medication, or existing prior to the time of and worsening after the time of the first dose of randomized study medication. Subjects experiencing multiple episodes of a given adverse event are counted once. This was a 84 day study and adverse event reporting was upto day 84.", "eventGroups": [{"id": "EG000", "title": "FDC 125", "description": "Leucine 1100mg +Metformin 125mg", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 2, "otherNumAtRisk": 12}, {"id": "EG001", "title": "FDC 250", "description": "Leucine 1100mg +Metformin 250mg", "deathsNumAffected": 0, "deathsNumAtRisk": 16, "seriousNumAffected": 1, "seriousNumAtRisk": 16, "otherNumAffected": 2, "otherNumAtRisk": 16}, {"id": "EG002", "title": "FDC 500", "description": "Leucine 1100mg +Metformin 500mg", "deathsNumAffected": 0, "deathsNumAtRisk": 11, "seriousNumAffected": 0, "seriousNumAtRisk": 11, "otherNumAffected": 2, "otherNumAtRisk": 11}, {"id": "EG003", "title": "Control", "description": "850mg Metformin", "deathsNumAffected": 0, "deathsNumAtRisk": 11, "seriousNumAffected": 0, "seriousNumAtRisk": 11, "otherNumAffected": 1, "otherNumAtRisk": 11}], "seriousEvents": [{"term": "Chest Pain", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}]}], "otherEvents": [{"term": "Gastric Disorders", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}]}, {"term": "Endocrine", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}]}, {"term": "musculoskeletal", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 11}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}]}, {"term": "Respiratory dsorders", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}]}, {"term": "Cough", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}]}, {"term": "Diarrhoea", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 11}]}, {"term": "Ecchymosis", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}]}, {"term": "Hyperglycemia", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}]}, {"term": "Fatigue", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}]}, {"term": "Chest Pain", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 16}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 11}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": true}, "pointOfContact": {"title": "Barbara Cannon", "organization": "NuSirt Biopharma", "email": "BCannon@nusirt.com", "phone": "615-656-7898"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "T10", "name": "Leucine", "asFound": "Exploration", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AA", "name": "Amino Acids"}]}}, "hasResults": true}